Abstract
The WHO has highlighted the threat of emerging carbapenem-resistant (CR) gram-negative pathogens which are resistant to multiple antibiotics. Cefiderocol, a new parental antibiotic is the first to address all three WHO priority pathogens. To determine the cost-effectiveness of cefiderocol compared to ceftazidime/avibactam, modelling results for the treatment of seriously ill patients with complicated Urinary Tract Infections (cUTI), Pneumonia and Bloodstream infection (BSI)/sepsis caused by suspected CR pathogens (Enterobacterales, Acinetobacter Spp., Stenotrophomonas Spp., Pseudomonas Spp) in Italy was analysed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
